Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Neumora Therapeutics, Inc. (NMRA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.85, with a market capitalisation of $187.78M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.83 to $3.65. This page covers its latest market performance, valuation, price trends and company information.
$187.78M | |
$0.85 | |
$21.00 | |
$0.61 | |
$0.83 | |
2.83K | |
1.62M | |
-- | |
$3.65 | |
$0.83 | |
-- | |
-- |
Neumora Therapeutics, Inc. (NMRA) is trading at $0.85 in pre-market trading as of 2026-09-16 08:21:00, up 2.25% ($0.02) from the previous close of $0.83
Pre-market trading shows how investors are pricing NMRA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Neumora Therapeutics, Inc. (NMRA) moved from $1.31 to $0.85, representing a decline of 35.11% ($0.46).
The stock traded between $0.83 and $1.36 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 907.23 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.7%
NMRA is currently trading at $0.85, placing it 0.7% of the way from its 52-week low of $0.83 to its 52-week high of $3.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 63 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Neumora Therapeutics, Inc. (NMRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.